Mary Moller
Psychiatric/Mental Health, Adult · Tacoma, WANPI 1770582884
Payments from drug & device makers
Across 913 payments — averaging $575.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$395K
- Axsome Therapeutics, Inc.$58K
- E.r. Squibb & Sons, L.L.C.$45K
- Teva Pharmaceuticals USA, Inc.$12K
- Bioxcel Therapeutics, Inc.$5K
- Alkermes, Inc.$4K
- plus $7K from 10 others
What the payments were for
- Consulting fees$53,61910%
- Speaking & faculty fees$368,04070%
- Travel & lodging$90,63917%
- Food & beverage$13,4703%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 684 | $394,693 |
| Axsome Therapeutics, Inc. | 91 | $58,346 |
| E.r. Squibb & Sons, L.L.C. | 77 | $45,237 |
| Teva Pharmaceuticals USA, Inc. | 10 | $12,028 |
| Bioxcel Therapeutics, Inc. | 4 | $4,634 |
| Alkermes, Inc. | 9 | $3,773 |
| Sumitomo Pharma America, Inc. | 1 | $3,224 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $1,295 |
| Sage Therapeutics, LLC | 1 | $964 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 14 | $728 |
| AbbVie | 7 | $306 |
| Neurocrine Biosciences, Inc. | 5 | $240 |
| Boehringer Ingelheim | 2 | $138 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $101 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Lundbeck LLC | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$380,812
- Auvelity$56,830
- COBENFY$42,592
- ARISTADA$10,580
- IGALMI$4,620
- ARISTADA INITIO$2,645
- TRINTELLIX$1,295
- Zurzuvae$964
- INGREZZA$128
- VRAYLAR$120
- Austedo XR$119
How this compares
Too few psychiatric/mental health, adult providers in Washingtonto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 18 | $2,169 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 13 | $1,439 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 18 | $1,011 |
| Modafinil | 12 | $601 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health, adult in Tacoma
- Michael KennedySeattle$94
- Jessica WheelerTumwater$27
- Denise HughesBremerton$25
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.